SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-264162
Filing Date
2023-10-26
Accepted
2023-10-26 17:01:00
Documents
18
Period of Report
2023-10-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d512767d8k.htm   iXBRL 8-K 29797
2 EX-4.1 d512767dex41.htm EX-4.1 72339
3 EX-5.1 d512767dex51.htm EX-5.1 14669
4 EX-10.1 d512767dex101.htm EX-10.1 106954
5 EX-99.1 d512767dex991.htm EX-99.1 10210
9 GRAPHIC g512767g1026185919418.jpg GRAPHIC 4602
10 GRAPHIC g512767g1026185941264.jpg GRAPHIC 2746
  Complete submission text file 0001193125-23-264162.txt   437017

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA glue-20231026.xsd EX-101.SCH 2852
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE glue-20231026_lab.xml EX-101.LAB 18739
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE glue-20231026_pre.xml EX-101.PRE 11709
12 EXTRACTED XBRL INSTANCE DOCUMENT d512767d8k_htm.xml XML 3474
Mailing Address 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118
Business Address 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118 617-949-2643
Monte Rosa Therapeutics, Inc. (Filer) CIK: 0001826457 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40522 | Film No.: 231350898
SIC: 2836 Biological Products, (No Diagnostic Substances)